Background: Janus kinase (JAK) inhibitors are emerging as a promising new treatment modality for many inflammatory conditions.
Objective: Our aim was to systematically review the available data on the use of JAK inhibitors in cutaneous diseases.
Methods: This is a systematic review of PubMed and ClinicalTrials.gov.
Results: One hundred thirty-four articles matched our search terms, of which 78 were original articles and 12 reports on adverse events. Eighteen clinical trials were found. JAK inhibitors have been extensively studied for psoriasis, showing beneficial results that were comparable to the effects achieved by etanercept. Favorable results were also observed for alopecia areata. Promising preliminary results were reported for vitiligo, dermatitis, graft versus host disease, cutaneous T cell lymphoma, and lupus erythematosus. The most common adverse events reported were infections, mostly nasopharyngitis and upper respiratory tract infections.
Limitations: It was not possible to perform a meta-analysis of the results.
Conclusions: This systematic review shows that while JAK inhibitors hold promise for many skin disorders, there are still gaps regarding the correct dosing and safety profile of these medications for dermatologic indications. Additional trials are necessary to address these gaps.
Keywords: JAK inhibitors; alopecia areata; atopic dermatitis; baricitinib; dermatology; graft versus host disease; psoriasis; ruxolitinib; tofacitinib; vitiligo.
Copyright © 2016 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.